Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

62.5%

5 terminated/withdrawn out of 8 trials

Success Rate

16.7%

-69.8% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A

2(33.3%)

Phase 4

2(33.3%)

Phase 3

1(16.7%)

Phase 1

1(16.7%)

6Total

N/A(2)

Phase 4(2)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07335523Not Yet Recruiting

Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation

Role: lead

NCT07418593Phase 4Recruiting

Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic Pancreatitis

Role: collaborator

NCT01652157Terminated

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Role: collaborator

NCT02985801Phase 1Terminated

PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

Role: collaborator

NCT00744250Phase 4Terminated

Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control

Role: lead

NCT00749099Not ApplicableTerminated

Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum)

Role: lead

NCT00432861Phase 3Completed

Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis